Business
Hardman & Co Res: BIVV deal establishes structure
Hardman & Co Res: BIVV deal establishes structure.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 1529G Oxford Biomedica PLC 28 February 2018 \n\nHardman & Co Res: BIVV deal establishes structure\nBioverativ deal - establishes structure: Oxford BioMedica (OXB) is a specialist advanced therapy lentivirus-based vector biopharma company. It offers vector manufacturing and development services and is developing its own proprietary drug candidates. In addition to LentiVector® service contracts, OXB will receive royalties on commercial therapies developed with its platform. This deal structure was established with Novartis for Kymriah™, the first approved CAR-T therapy, and has now been followed by a collaboration and licence agreement adopting a similar structure with Bioverativ Inc (BIVV), for the development and potential clinical supply of vector to treat haemophilia.\nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/28.02.18-bioverativ-deal-establishes-structure.pdf\n\n\n\n\nTo contact us:\nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\nwww.hardmanandco.com\nFollow us on Twitter @HardmanandCo\n\n\nContacts:\nDr Martin Hall\nDr Dorothea Hill\nDr Gregoire Pave\n\n+44 20 7194 7622\n\n\n \[email protected]@[email protected]\n\n\n\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high...